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Abstract
Sphingosine kinase is a lipid kinase that converts sphingosine into sphingosine-1-phos-
phate, an important signaling molecule with intracellular and extracellular functions.
Although diverse extracellular stimuli influence cellular sphingosine kinase activity, the
molecular mechanisms underlying its regulation remain to be clarified. In this study, we
investigated the phosphorylation-dependent regulation of mouse sphingosine kinase
(mSK) isoforms 1 and 2. mSK1a was robustly phosphorylated in response to extracellular
stimuli such as phorbol ester, whereas mSK2 exhibited a high basal level of phosphoryla-
tion in quiescent cells regardless of agonist stimulation. Interestingly, phorbol ester-induced
phosphorylation of mSK1a correlated with suppression of its activity. Chemical inhibition of
conventional PKCs (cPKCs) abolished mSK1a phosphorylation, while overexpression of
PKCα, a cPKC isoform, potentiated the phosphorylation, in response to phorbol ester. Fur-
thermore, an in vitro kinase assay showed that PKCα directly phosphorylated mSK1a. In
addition, phosphopeptide mapping analysis determined that the S373 residue of mSK1a
was the only site phosphorylated by cPKC. Interestingly, alanine substitution of S373 made
mSK1a refractory to the inhibitory effect of phorbol esters, whereas glutamate substitution
of the same residue resulted in a significant reduction in mSK1a activity, suggesting the sig-
nificant role of this phosphorylation event. Taken together, we propose that mSK1a is nega-
tively regulated through cPKC-dependent phosphorylation at S373 residue.
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Introduction
Sphingolipids such as ceramide, sphingosine (SPH), and sphingosine-1-phosphate (S1P) are
ubiquitous constituents of eukaryotic membranes that regulate cell growth, survival, apoptosis,
differentiation, migration, and immune responses [1–4]. In contrast to ceramide and SPH,
which are associated with apoptosis, S1P has been clearly established as a pro-survival molecule
[5], as well as an important regulator of cellular trafficking, differentiation, angiogenesis, and
inflammation [5]. S1P acts as both an intracellular second messenger and an extracellular
ligand [1–4, 6, 7]. Inside cells, S1P is important for direct modulation of the activity of histone
deacetylase [7], the ubiquitin ligase activity of TRAF2 [8], activation of MAP kinase [9], and
Ca2+ mobilization [10, 11]. In another context, S1P functions as an extracellular ligand for a
family of S1P-specific cell-surface G protein-coupled receptors (GPCRs) [5, 12]. In addition,
S1P is generated in and released from multiple types of cells [1]. Five S1P receptors (S1P1-5)
interact with S1P at the plasma membrane and then signal downstream via various G proteins
including Gq, Gi/o, and G12/13, allowing for cell type-specific responses [1, 5, 12].
Sphingosine kinase (SK) is a lipid kinase that converts SPH into S1P by ATP-dependent
phosphorylation [3]. The level of S1P in the cell is regulated in response to extracellular stimuli,
probably by adjusting the balance between SK-mediated synthesis and degradation by SPP
lyase or phosphatase [1]. To date, it is not clear that the activity of S1P lyase or phosphatase is
transiently regulated; by contrast, many studies have established that the activity of cellular SK
is regulated dynamically in the context of cellular physiology [3]. Indeed, SK is activated by
multiple stimuli, including as PDGF [13], serum [13, 14], TNFα [15], NGF [16], VEGF [17],
acetylcholine [18, 19], phorbol ester [20], forskolin [21], and FcgRII ligation [22], and formyl
peptide [23]. On the other hand, SK activity could be negatively regulated in response to extra-
cellular stimuli. For example, HDL profoundly inhibits TNF-stimulated sphingosine kinase
activity in endothelial cells, resulting in decreased S1P production [24]. Despite extensive stud-
ies about the physiological roles of SK and its product S1P, the molecular mechanisms underly-
ing SK regulation have remained largely unclear.
The mouse genes,mSK1 andmSK2, encode the mSK1 and mSK2 proteins, respectively, each
of which has multiple splice variants that differ only at the N-terminus [1, 5]. Just like the human
isoforms, mSK1 and mSK2 exhibit different tissue distributions and subcellular location patterns
[25]. Genetic knockout of each SK isoform has confirmed that the two isoforms may have dis-
tinct physiological functions [26–29], in addition to some functional redundancy [30, 31]. Except
for the catalytic domains, the two SK isoforms differ significantly in protein sequence and molec-
ular structure [1, 32, 33]. mSK1 harbors multiple Ca2+/calmodulin-binding sequences [32] and
both isoforms have a proline-rich motif that might be involved in the interaction with SH3
domain-containing protein(s) [33], suggesting that the two isoforms might be differentially regu-
lated through both specific and common signaling pathways. However, the possibility that each
mSK isoform is regulated by distinct phosphorylation event has not been explored yet.
In this study, we analyzed the phosphorylation pattern of mSK isoforms in response to
extracellular stimuli. Based on the initial observation that mSK1a is robustly phosphorylated in
response to phorbol ester, we characterized the molecular pathway leading to mSK1a phos-
phorylation and elucidated its influence on SK activity.
Material and Methods
Materials
S1P and SPH were from Biomol (Enzo Life Sciences, US). [32P]ATP was purchased from Perki-
nElmer NEN Products (Boston, MA, USA). Phorbol 12-myristate 13-acetate (PMA), 4-deoxy
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pyridoxine, GF109204X, Go6976, and RO-31-8220 were fromMerck Millipore (San Diego,
USA). Silica TLC G60 plate was from Merck Millipore. Serum and medium were obtained
from HyClone (Logan, UT), and other chemicals were from Sigma-Aldrich (St. Louis, USA).
Cell culture
COS-7 cells (from ATCC) were maintained in Dulbecco's modified Eagle's medium supple-
mented with 10% FBS. Cells were grown at 37°C in humidified atmosphere containing 5% CO2.
Immunoblot Analysis
Cell lysates (30 μg) were resolved by 12% SDS-PAGE and transferred to NCmembrane (Schlei-
cher & Schuell Bioscience). Membranes were blocked by incubation for 30 min at room tem-
perature with T-TBS (TBS and 0.1% (v/v) Tween 20) containing 5% (w/v) nonfat milk.
Primary antibodies were incubated overnight at 4°C in the blocking buffer at the appropriate
dilutions. The bound primary IgGs were detected by incubation with secondary antibodies
conjugated to HRP and developed using the ECL system (GE Healthcare Life Sciences).
Plasmid construction and mutagenesis
IMAGE clones 4221357 (mSK1a) and 2650442 (mSK2) were obtained from the Human
Genome Mapping Project Resource Centre in UK and verified by direct sequencing with
appropriate primers. Full-length cDNAs were amplified with PCR using primer pairs for
mSK1a (5’-gc gaa ttc atg gaa cca gaa tgc cct cga-3’/5’-gc gga tcc tta tgg
ttc ttc tgg agg tgg- 3’) and mSK2 (5’-ccc aag ctt atg gcc cca cca cca cta
ctg-3’/ 5’-ccg gaa ttc tca ggc ttg tgg ctt ttg acc-3’). The PCR products
were digested with EcoRI/BamHI (for mSK1a) orHindIII/EcoRI (for mSK2), and subsequently
ligated into pCMV2-FLAG.
Site-directed mutagenesis was carried out using the splice-overlap extension method. For
the substitution of S373 with alanine, PCR was carried out with wild-type (WT) mSK1a as the
template DNA, the forward primer 5'- ggc cgg gac gcc cgg cgg ggg- 3’, and the
reverse primer 5’- ccc ccg ccg ggc gtc ccg gcc-3’. From the PCR product, the
EcoRI/BamHI fragment was cloned into pCMV2-FLAG. The strategy was used to generate the
other mutations using the following oligonucleotides: forward primer, 5’-aga ccc gcc gcc
aca ctg gtg-3’/reverse primer, 5’-cac cag tgt ggc ggc ggg tct-3’ (S225A); for-
ward primer, 5’-gag ccc agg gcc cag agg ggc-3’/reverse primer, 5’-gcc cct ctg
ggc cct ggg ctc-3’ (S332A); forward primer, 5’-ggc cgg gac gcg cgg cgg ggg-
3’/reverse primer, 5’-ccc ccg ccg cgc gtc ccg gcc-3’ (S373A); and forward primer,
5’-ggc cgg gac gag cgg cgg ggg-3’/reverse primer, 5’-ccc ccg ccg ctc gtc ccg
gcc-3’ (S373E). All mutations were verified by direct sequencing of the entire ORFs while
confirming the absence of undesired mutations.
Transfection
COS-7 cells were plated on 35 mm or 10 cm culture dishes at a density of 1.5 × 105 or 7 × 105
cells/dish, respectively. The next day, 1–4 μg of plasmid DNAs (pCMV2-control,
pCMV2-mSK2, pCMV2-mSK1a WT, pCMV2-mSK1a S373A, pCMV2-mSK1a S373E,
pCMV2-mSK1a S225A, pcDNA3.1, pcDNA3.1 PKCα, or pcDNA3.1 PKCδ) were transfected
using the Lipofectamine 2000™ reagent (Life Technologies). Transfected cells were serum-
deprived for 24 hrs before agonist stimulation and then stimulated with agonists for the indi-
cated times.
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Measurement of SK Activity
In vitro SK assay. As described previously with minor modifications [34], the cells were
washed with ice-cold PBS and scraped in SK assay buffer (20 mM Tris buffer [pH 7.2], 10 mM
MgCl2, 20% glycerol, 1 mM dithiothreitol, 1 mM EDTA, 1 mMNa3VO4, 15 mM NaF, 10 μg/
ml leupeptin and aprotinin, 1 mM PMSF, and 0.5 mM 4-deoxypyridoxine). For cell lysis, cells
were ruptured by sonication (Branson Sonifier, output control 3) in SK assay buffer supple-
mented with 0.25% Triton X-100. Cell homogenates were centrifuged at 15,000 rpm to remove
the insoluble fraction. SK activity in cell extracts was measured by incubation in SK assay buffer
with 50 μM SPH, solubilized in 0.25% Triton X-100 and 1 mM [32P] ATP for 20 min at 37°C.
The labeled lipids were extracted and resolved by TLC in the solvent of 1-butanol/ethanol/ace-
tic acid/water (8:2:1:2). The formation of S1P was visualized and quantitated on a PhosphoI-
mager system (Fuji Film, Tokyo).
Measurement of [3H] S1P formation. COS-7 cells, transfected with either control or
mSK1a constructs, were serum-deprived for 24 hrs. The transfected cells were equilibrated in
DMEM containing 1 mg/ml fatty acid-free BSA for 30 min, and then the medium was replaced
with serum-free DMEM containing [3H]SPH (5 × 105 cpm, final concentration ~15 nM) pre-
loaded onto 1 mg/ml fatty acid-free BSA, together with PMA (100 nM) or vehicle. After incu-
bation for 5 min, the assay medium was replaced with 1 ml of pre-chilled methanol. The lipids
were extracted, dried, and resolved by TLC in 1-butanol:acetic acid:water (3:1:1) as described
previously [18]. SPH (Rf 0.67) and S1P (Rf 0.51) spots were visualized by ninhydrin and
molybdenum blue staining. Each spot was scraped off, and radioactivity was measured by liq-
uid scintillation counter.
Immuno-affinity Purification of mSK1a
After transfection with mSK1a, COS-7 cells were lysed and sonicated in lysis buffer A (20 mM
Tris, pH 8.0, 1 mM EDTA/EGTA, 0.1 mM DTT) supplemented with 0.25% Triton X-100 and
protease inhibitors (1 mM PMSF, 10 μg/ml leupeptin, and 10 μg/ml aprotinin). The lysates
were centrifuged at 15,000 rpm for 20 min at 4°C. The supernatants were incubated at 4°C
overnight with constant agitation with 50 μl of α-FLAG (M2 clone) Affi-Gel (Sigma-Aldrich,
USA). The resin was washed four times with 1 ml of lysis buffer A. Bound protein was eluted
with lysis buffer A containing 4 μg/ml 3×FLAG peptide (Sigma-Aldrich).
Expression and Purification of PKCα
Recombinant baculovirus expressing PKCα was a generous gift from Dr. W. Cho (University
of Illinois). PKCα was expressed in baculovirus-infected Sf9 cells and purified as described
with some modifications [35]. Monolayers of Sf9 cells (2 × 107 cells/150 mm dish, ten dishes)
were infected at a multiplicity of infection of 10. PKCα was purified using Hitrap-Q FPLC, fol-
lowed by Phenyl-Superose FPLC (GE Healthcare Life Sciences). The purity of PKCα was
assessed higher than 90% by SDS-PAGE and Coomassie stain.
In vivo and in vitro 32P-labeling mSK1a and Purification
For in vivo phosphorylation, COS-7 cells in 60 mm dishes were transfected with mSK1a plas-
mid and metabolically labeled with [32P] inorganic phosphate (0.4 mCi) in 2 ml of phosphate-
free DMEM for 3 hrs. After PMA (100 nM) treatment for 10 min, cells were washed twice with
ice-cold PBS, lysed in 500 μl of lysis buffer (20 mM Tris [pH 7.4], 1 mM EDTA, 1 mM EGTA,
15 mMNaF, 1 mM Na3VO4, 30 mM sodium pyrophosphate, 10 mM β-glycerophosphate, 1%
Triton X-100, 20% glycerol) containing protease inhibitors, and centrifuged at 15000×g for 5
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min at 4°C. mSK1a was isolated with α-FLAG Affi-Gel, separated with SDS-PAGE, electro-
blotted onto NC membrane, and analyzed by autoradiography.
In vitro phosphorylation by PKC was carried out under standard kinase assay conditions.
Briefly, recombinant mSK1a (50 ng) was incubated with purified PKCα (10 ng) in the presence
or absence of 1 μM PMA in a total volume of 50 μl of PKC assay buffer (50 mMMES [pH 6.5],
1.25 mM EDTA, 12.5 mMMgCl2) containing 2.5 μCi of [
32P]-ATP and 10 μMATP for the
times specified at 30°C. Reactions were terminated by adding 12.5 μl of 5×SDS sample buffer
and boiling for 5 min. Proteins were separated by SDS-PAGE and electro-blotted onto NC
membrane. The phosphorylated protein bands were localized by autoradiography to Phos-
phoImager or photographic film.
Phosphopeptide Mapping and Phospho-amino Acid Analysis
In vivo immunoprecipitated or in vitro 32P-labeled mSK1a was resolved by 10% SDS-PAGE
and electro-blotted onto NC membrane. Two-dimensional phosphopeptide mapping of phos-
phorylated mSK1a and phosphoamino acid analysis were carried out on a Hunter thin layer
electrophoresis system (CBS Scientific Company, Del Mar, CA, USA) as described previously
[36]. Briefly, phosphorylated mSK1a proteins were separated by SDS-PAGE. mSK1a protein
was washed and digested with trypsin for 12 hrs at 37°C before the addition of another 2 μg of
trypsin; the total incubation time was 24 hrs. The phosphopeptides were separated by two-
dimensional chromatography.
Phosphoamino acid analysis was performed essentially as described previously [36]. Phos-
phopeptides localized by autoradiography were scraped and eluted from the cellulose matrix
with 200 μl of pH 1.9 buffer. Acid-hydrolyzed phosphopeptides were separated by two-dimen-
sional electrophoresis using the HTLE 7000 electrophoresis system. Standard amino acids (ser-
ine, threonine, and tyrosine) were visualized with ninhydrin, and the phosphoamino acid
content of mSK1a was analyzed by autoradiography.
Phosphate-release assays were performed utilizing Edman degradation chemistry. Aliquots
of purified phosphopeptides were covalently linked to a Sequelon AA filter using the Sequelon
AA reagent kit (Millipore), and phosphate was extracted from each cycle with three 0.5 ml ali-
quots of 90% methanol/0.015% phosphoric acid as the solvent. Fractions from each cycle were
collected and counted in a liquid scintillation counter.
Two-dimensional Gel Electrophoresis of mSK1a
A ready-to-use immobilized pH gradient strip (GE Healthcare Life Sciences) was rehydrated
for 12 hrs in 2D lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 2% DTT, protease inhibitors,
and phosphatase inhibitors). mSK1a-containing immune complex was solubilized by 2D lysis
buffer with gentle vortexing for 1 hr at room temperature. Sample was applied to the rehy-
drated strips and run on a horizontal MultiPhorII IEF unit. Second-dimension gel electropho-
resis was performed as specified by the manufacturer (GE Healthcare Life Sciences).
Immunoblotting was performed as described elsewhere.
Calmodulin-affinity Binding Analysis
Purified mSK1a proteins (0.5 μg) were incubated with 50 μl of Calmodulin (CaM)-Sepharose
4B beads (GE Healthcare Life Sciences), equilibrated with binding buffer (20 mMHEPES [pH
7.4], 200 mM KCl, 0.1% Triton X-100, 20% glycerol) supplemented with the indicated concen-
trations of free Ca2+ ions. The mixtures were incubated for 3 hrs at 4°C with continuous mix-
ing. Unbound proteins were removed by washing three times with binding buffer containing
free Ca2+ ion. Proteins bound to CaM–Sepharose beads were boiled in 1×Laemmli sample
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buffer and separated by SDS-PAGE and electro-blotted onto NC membrane. The blot was
probed with α-FLAG antibody. Sepharose CL-4B (GE Healthcare Life Sciences) was used as a
negative control to monitor the level of nonspecific binding of mSK1a to the beads themselves.
Results
PMA-induced phosphorylation of mSK1a
To investigate the mechanism of post-translational regulation of the mouse SK (mSK) iso-
forms, mSK1a and mSK2, we first examined whether these proteins were phosphorylated in
response to external stimuli. After overexpression of either mSK1a or mSK2 and 32P metabolic
labeling, we treated COS-7 cells with various types of extracellular stimuli, including PMA, for-
skolin, and epidermal growth factor (EGF), that have been previously identified as activators of
human SK isoforms [13, 20, 21, 37, 38]. Consistent with a previous study of hSK isoforms [21,
37, 38], phosphorylation of mSK1a is strongly induced in response to PMA, and to a lesser
extent by EGF. By contrast, the basal level of mSK2 phosphorylation remained high, even in
quiescent cells subjected to serum withdrawal, and agonist stimulation did not alter mSK2
phosphorylation markedly as shown in mSK1a (Fig 1). These results revealed that the phos-
phorylation levels of mSK1a and mSK2 are differentially regulated in response to extracellular
stimuli. In particular, mSK1a is robustly phosphorylated by PMA stimulation, suggesting a
possibility that mSK1a is regulated by this phosphorylation event.
Fig 1. Phosphorylation of mSK isoforms in response to extracellular stimuli.COS-7 cells were
transfected with control vector, FLAG-tagged mSK1a, or FLAG-tagged mSK2 constructs. After serum
deprivation and metabolic labeling with [32P] inorganic phosphate, the cells were treated for 10 min with
various agonists, as indicated: PMA (100 nM), EGF (100 ng/ml), or forskolin (20 μM). mSK isoforms were
immunoprecipitated using α-FLAG Affi-Gel, transferred on nitrocellulose membrane, and exposed to X-ray
photographic film (top panel) after Ponceau S staining (bottom). This result is representative of three
independent experiments.
doi:10.1371/journal.pone.0143695.g001
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Inverse correlation between mSK1a phosphorylation and its activity
Next, we examined the correlation between mSK1a phosphorylation and enzyme activity.
When measured over a time course, mSK1a phosphorylation progressively increased in
response to PMA treatment up to 4.5-fold (Fig 2A), whereas its in vitro activity was suppressed
(Fig 2B). Furthermore, we observed that PMA treatment resulted in the marked reduction of
cellular S1P formation in the mSK1a-transfected cells, by inhibiting its cellular activity (Fig
2C). These results strongly suggested that mSK1a is negatively regulated by PMA treatment
and that phosphorylation of mSK1a is closely related to the suppression of its activity.
Conventional PKC (cPKC)-dependent phosphorylation of mSK1a
PMA is a potent activator that stimulates multiple subclasses of PKC isoforms, including both
conventional (α, βI, βII, γ) and novel (δ, ε, η, θ) isozymes in various cell types [39]. To deter-
mine which PKC isozyme mediates PMA-induced mSK1a phosphorylation, we used two inde-
pendent approaches. First, we examined the effect of pharmacological PKC inhibitors, such as
PKC-nonselective RO-31-8220 [40], and PKCα/β1-selective Go6976 [41], on mSK1a phos-
phorylation. PMA-induced phosphorylation of mSK1a was completely abolished by pretreat-
ment with RO-31-8220 or Go6976 (Fig 3A). Second, we examined the effect of overexpression
of each isozyme on mSK1a phosphorylation. mSK1a phosphorylation was significantly
increased by overexpression of PKCα, a cPKC isoform, but not PKCδ, a novel PKC isoform
(Fig 3B), which suggests the specific PKC pathway mediates mSK1a phosphorylation. These
results suggested that the PKCα or possibly other cPKC isozymes mediates PMA-induced
phosphorylation of mSK1a in COS-7 cells.
After the functional role of cPKC upstream of mSK1a phosphorylation was established, it
remained unclear whether mSK1a is the direct substrate of cPKC. To address this question, we
conducted in vitro kinase assays by reconstituting purified mSK1a and PKCα in the presence
or absence of PMA. mSK1a was directly phosphorylated by PKCα, a cPKC isoform, in vitro, as
it is in vivo (Fig 3C). Furthermore, we compared the 2D-phosphopeptide maps derived from
mSK1a proteins phosphorylated in vitro and in vivo (Fig 3D). PMA treatment of cells overex-
pressing mSK1a led to the generation of two in vivo phosphopeptides (designated a and b). In
addition, one basal phosphopeptide (designated as c) was present irrespective of PMA treat-
ment. Notably, in vitro phosphorylation of mSK1a generated two phosphopeptides (designated
as 1 and 2) that completely overlapped with in vivo phosphopeptides a and b, respectively, as
revealed by analysis of the mixture (in vivo + in vitro, designated 1/a and 2/b). By contrast, in
vivo peptide c, which was not responsive to PMA treatment, was not present in mSK1a phos-
phorylated by PKCα in vitro. These data suggested that PKCα directly phosphorylates mSK1a,
at the same residue both in vivo and in vitro.
Determination of in vivo phosphorylation sites of mSK1a
To determine the PKC-dependent (a and b) and -independent (c) phosphorylation sites of
mSK1a, we extracted 32P-labeled phosphopeptides (Fig 4A). Purified phosphopeptides were
divided into two fractions; one was subjected to phosphoamino analysis and the other was sub-
jected to 32P release assay. Phosphoamino analysis revealed that all three phosphopeptides (a,
b, and c) exclusively harbor phosphoserine residues within their sequences (Fig 4B). Moreover,
32P release assay after Edman degradation revealed that the phosphoserine residues were
located in the first or second position in phosphopeptides a and b, and the fourth position of
phosphopeptide c, relative to the N-terminus generated by tryptic digestion (Fig 4C). On the
basis of this information, several candidates for each phosphopeptide were selected (Fig 4C).
We predicted that two sites (S332, S373) were putative sites for phosphopeptide a and b, and
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Fig 2. PMA-induced phosphorylation and inhibition of mSK1a. (A) Time-dependent phosphorylation of
mSK1a in response to PMA treatment. COS-7 cells were transfected with mSK1a cDNA. After metabolic
labeling with [32P] ortho-phosphate, the cells were treated with 100 nM PMA for indicated periods of time.
mSK1a was immunoprecipitated using the FLAG epitope. The autoradiogram and immunoblot images using
α-FLAG antibody are shown (top and middle panels), and relative radioactivity was quantitated in duplicate
(bottom). Data represent the means ± SE. (B) Time course of PMA-induced suppression of mSK1a activity.
COS-7 cells, transfected with mSK1a cDNA, were stimulated with 100 nM PMA for the indicated periods of
time. Data are from triplicate determinations from independent cultures, and are expressed as percentages
relative to untreated controls. Data represent the means ± SEM. (One-way ANOVA test, *p < 0.05,
**p < 0.01). (C) PMA-induced suppression of [3H]S1P formation by mSK1a. Formation of [3H]S1P was
determined in COS-7 cells that are transfected with either control vector or mSK1a cDNA, and further
stimulated with 100 nM PMA for 10 min prior to [3H]SPH labeling. Data represent the means ± SEM. (t-test,
*p < 0.05, **p < 0.01).
doi:10.1371/journal.pone.0143695.g002
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one of the others (S140, S225, S338, S369) was the putative site in phosphopeptide c. To deter-
mine the exact phosphorylation sites of mSK1a, we performed alanine mutagenesis at each of
these residues. Ala mutation at S373 (S373A) resulted in a marked reduction in the level of
mSK1a phosphorylation in response to PMA treatment (Fig 4D). Furthermore, comparison of
phosphopeptide maps revealed that the reduction of 32P-incorporation into the S373A mutant
was due to the disappearance of two PMA-responsive phosphopeptides, a and b (indicated by
arrowheads in the WT in Fig 4E). By contrast, mutation of S332, the other candidate, had no
effect on the level of 32P-incorporation. These data suggest that S373 of mSK1a is the only
phosphorylation site by PKCα. Because partial digestion occurs frequently in tandem Arg or
Lys residues in the protein sequence [42], the two phosphopeptides arising in response to PMA
Fig 3. Direct phosphorylation of mSK1a by cPKC. (A) Effect of PKC inhibition on mSK1a phosphorylation. COS-7 cells were transfected with FLAG-
tagged mSK1a and then labeled with [32P] ortho-phosphate. As indicated, the cells were treated with PKC inhibitors (10 μMRo-31-8220, or 0.5 μMGo6976)
for 15 min prior to PMA treatment (100 nM, 10 min). mSK1a immobilized onto nitrocellulose membrane (NC) was exposed to a photographic film (top). The
same NCmembrane was immunoblotted with anti-FLAG antibody (bottom). (B) Effect of PKC overexpression on PMA-induced mSK1a phosphorylation.
mSK1a cDNA were co-transfected with control vector or cDNAs encoding PKCα or PKCδ as indicated. Relative radioactivity of immunoprecipitated mSK1a
was visualized as described above (top panel), and the overexpression of each PKC isozyme was confirmed by immunoblot analysis of total homogenates
using antibodies specific for each isozyme (PKCα or PKCδ). (C) Direct phosphorylation of mSK1a by purified PKCα. One hundred nanograms of mSK1a
and/or 10 ng of PKCα were incubated in 25 μl of phosphorylation buffer containing [32P]-ATP in the presence or absence of 1 μMPMA for 20 min as
indicated. Incorporation of radioactivity was determined after separation of the reaction mixtures by gel electrophoresis and autoradiography. The upper
panel is an autoradiogram of NCmembrane corresponding to mSK1a and PKCα, respectively. The lower panel is an immunoblot of the same NCmembrane
showing that equal amounts of proteins were used in the phosphorylation reactions. (D) Comparison of mSK1a phosphopeptides phosphorylated in vitro and
in vivo. mSK1a phosphorylated in vivowas obtained from COS-7 cells after they were treated with PMA (In vivo +PMA) or not treated (In vivo -PMA). mSK1a
(in vitro +PMA) phosphorylated by PKCα in vitro was digested with TPCK-trypsin. The tryptic digests of in vivo and in vitro phosphorylated mSK1a, as well as
a mixture of the two (in vivo + in vitro), were subjected two-dimensional phosphopeptide mapping analysis consisting of electrophoresis and subsequent
chromatography. The arrowheads indicate two overlapping phosphopeptides (1/a, 2/b) and the arrow is for non-overlapping peptide (c).
doi:10.1371/journal.pone.0143695.g003
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Fig 4. mSK1a S373 is the cPKC-dependent phosphorylation site. (A) PKC-dependent (spots a and b: arrowheads) and -independent (spot c: arrow)
phosphopeptide(s) are indicated. Each peptide was eluted from the TLC plate and divided into two fractions, which were subjected to two-dimensional
phosphoamino acid analysis or 32P-release assay. (B) Phosphoamino acid analysis of three phosphopeptides. Acid-hydrolyzed peptides were subjected to
2-dimensional phosphoamino acid analysis. Dotted circles indicate the migration positions of phosphoserine (pS), phosphothreonine (pT), and
phosphotyrosine (pY) standards (left panel) and the image from autoradiography (right panel). (C) 32P-release assay of three radiolabeled peptides.
Radiolabeled peptides loaded onto the sequencing membrane (Millipore) were digested sequentially from the N-terminus by the Edman degradation method.
Putative candidate sites for each phosphopeptide were predicted based on the relative position from the tryptic cleavage site, as shown on the right. (D) Site-
directed mutagenesis of candidate sites. COS-7 cells were transfected with FLAG-tagged mSK1a constructs including wild-type (WT) and its mutant (S225A,
S332A, S373A) and treated with PMA (100 nM). The relative phosphorylation level of each mSK1a form was assessed in duplicate. Data represent the
means ± SE. (E) Two-dimensional phosphopeptide analysis of WTmSK1a and its S/A mutants (S225A, S332A, S373A). cPKC-dependent spots (a and b)
and -independent spot (c) are indicated by arrowheads and arrow, respectively. (F) In vitro phosphorylation of WTmSK1a and its S/A mutants by PKCα.
Wild-type mSK1a and S/A mutants (S373A, S225A) were expressed in COS-7 cells and purified using α-FLAG Affi-Gel. Each protein (100 ng) was incubated
with PKCα (10 ng) in 1× phosphorylation buffer in the presence or absence of PMA and GF109204X (GFX). Incorporation of radioactivity was measured, and
the transferred membrane was immunoblotted to monitor the input amount of each protein, as indicated.
doi:10.1371/journal.pone.0143695.g004
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treatment are likely to be generated from partial tryptic digestion of tandem Arg residues in
Asp-phosphoSer-Arg-Arg-Gly into two similar peptides, Asp-phosphoSer-Arg and Asp-phos-
phoSer-Arg-Arg. The in vitro PKC assay revealed that S373 is the only PKCα phosphorylation
site in mSK1a. PKCα can phosphorylate WT mSK1a and the S225A mutant, but not the S373A
mutant (Fig 4F). These data clearly showed that the S373 residue, located in the C-terminus of
mSK1a, is the direct phosphorylation site of PKCα.
In addition, Ala mutation at S225 (S225A) resulted in a marginal reduction in the level of
mSK1a phosphorylation in response to PMA treatment (Fig 4D). Furthermore, comparison of
phosphopeptide maps revealed that the slight decrease of 32P-incorporation into the S225A
mutant was due to the disappearance of phosphopeptide c (indicated by arrows in the WT in
Fig 4E), confirming that S225 is a basal phosphorylation site that is not responsive to PMA
treatment. Furthermore, we examined the relationship between different phosphorylation
sites. Phosphorylation at S373 was not affected by mutation at S225 (Fig 4F). Conversely, muta-
tion at S373 had no effect on the phosphorylation level at S225. Thus, phosphorylation of S373
and S225 occur under independent control.
PMA-induced mSK1a inhibition is abolished by S373A mutation
We next examined whether S373 phosphorylation of mSK1a results in an alteration in its activ-
ity. Wild-type (WT) mSK1a was phosphorylated and inhibited in a time-dependent manner,
whereas the S373A mutant, which was defective in phosphorylation, was refractory to inhibi-
tion by PMA treatment over all time periods examined (Fig 5A). Furthermore, we tried to esti-
mate the level of mSK1a phosphorylation by separating phosphorylated and unphosphorylated
mSK1a by 2-D gel electrophoresis. In WT transfected cells, but not S373A-transfected cells,
PMA treatment shifted mSK1a toward acidic field concomitant with the appearance of addi-
tional mSK1a spots, which may be attributable to the generation of a phosphorylation-depen-
dent negative charge in mSK1a (Fig 5B). The phosphorylation level could be roughly estimated
at around 20–30% of total mSK1a, roughly correlated with the level of mSK1 inhibition in
response to PMA treatment. To determine whether S373 phosphorylation is sufficient to
inhibit mSK1a activity, we analyzed the effects of S373E mutagenesis, mimicking the phos-
phorylated state of S373. The activity of WT mSK1a was inhibited after PMA treatment,
whereas the S373E mutant was constitutively inactive irrespective of PMA treatment (Fig 5C),
suggesting that S373 phosphorylation plays a significant role in inhibiting mSK1a activity.
Next, we investigated whether alteration in SK activity as a result of the S373E mutation is a
result of the aberrant folding of the protein itself. Previous work showed that correctly folded
hSK1 protein interacts with Ca2+-bound calmodulin [43], which provides an indicator for the
proper protein folding of SK1a. Hence, we conducted calmodulin-binding analysis with WT
mSK1a and the S373E mutant at two different concentrations of Ca2+ ion. We observed that
mSK1 interacted with calmodulin in a Ca2+ concentration-dependent manner. Importantly,
the S373E mutation did not alter its calmodulin interaction under any conditions tested (Fig
5D), suggesting that altered activity of mSK1a S373 mutant is unlikely to aberrant protein fold-
ing during protein synthesis. We have further examined whether the S373 mutation of mSK1a
influences on protein-protein interactions of mSK1a. While multiple proteins were found co-
precipitated with mSK1a, we couldn’t detect any clear difference between WTmSK1a and the
S373 mutant (S1 Fig).
Discussion
SK is regulated by a wide variety of extracellular stimuli in order to mediate multiple physiolog-
ical functions [1, 3, 5, 44, 45]. However, the detailed molecular mechanisms underlying SK
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regulation remain incompletely understood. In this study, we explored the phosphorylation-
dependent regulation of mSK1a. We observed that S373 of mSK1a is directly phosphorylated
by cPKC in response to PMA treatment. Furthermore, this phosphorylation results in the inhi-
bition of mSK1a activity.
Although previous work showed that mSK1a contains several consensus motifs for phos-
phorylation by protein kinases such as PKA, casein kinase II, and PKC [32], the physiological
relevance of putative phosphorylation events in mSK1a have not been rigorously tested. Our
results demonstrate that phosphorylation of mSK1a is strongly elicited by PMA, a potent
Fig 5. S373 phosphorylation-dependent Inhibition of mSK1a. (A) The effect of mSK1a S373Amutation on PMA-induced inhibition of mSK1a activity.
Wild-type (WT) mSK1a or the S373A mutant was transfected into COS-7 cells. One day after transfection, the cells were serum-deprived for 24 hr and
treated with 100 nM PMA for the indicated periods of time. Protein extracts from COS-7 cells were assayed for SK activity in vitro. SK activity is expressed as
the percentage of activity relative to the non-treated control. These data represent the means ± SEM. Inset: time-dependent phosphorylation of WTmSK1a
and the S373A mutant (S373A). (B) Approximate stoichiometry of mSK1a phosphorylation. After PMA stimulation, WTmSK1a and its S373A mutant were
immunoprecipitated and subjected to 2-D gel electrophoresis. mSK1a was detected using immunoblot analysis using α-FLAG Ab. S373-phosphorylated (P-
mSK1a, red) and unphosphorylated (un-P-mSK1a, blue) proteins are indicated below the images. (C) Effect of mSK1a S373Emutation on PMA-induced
inhibition of mSK1a activity. Wild-type mSK1a and the S373E mutant were purified from transfected COS-7 cells using α-FLAG Affi-Gel. The same amounts
(5 ng) of purifiedWTmSK1a and S373Emutant were assayed for SK activity. The data are the means ± SEM (t- test, *p < 0.05, **p < 0.01). Inset: The
amounts of purified mSK1a and S373Emutant were confirmed by SDS-PAGE followed by Coomassie Blue (CBB) Staining. (D) Calmodulin interaction of WT
mSK1a and the S373 mutant. Identical concentrations of mSK1a and the S373Emutant were incubated with either calmodulin-agarose beads or control
beads at two different Ca2+ concentrations, as indicated. mSK1a bound to beads were assessed by immunoblotting using α-FLAG antibody. See also S1 Fig
for additional data about the protein interactions of WTmSK1a and the S373E mutant.
doi:10.1371/journal.pone.0143695.g005
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activator of PKC, but not by forskolin, an activator of PKA, indicating that this phosphorylation
of mSK1a is kinase-specific. Our results also showed that cPKC including PKCα, phosphory-
lates mSK1a both in vivo and in vitro. Mutation at S373 of mSK1a completely abolishes mSK1a
phosphorylation in response to PMA treatment, confirming that S373 is the sole site phosphor-
ylated by cPKC. Notably, peptide sequences surrounding S373 residue of mSK1a (-pS-R-R-G-)
are consistent with the representative consensus motif for cPKC phosphorylation, -[pS/pT]-
[_/F/K/V/L/Q/V]-[K/R]-[K/R/G]- [46], further confirming mSK1a as a novel substrate of acti-
vated cPKC within cells. cPKC isoforms including PKCα, -β, and -γ phosphorylate a number of
common substrates including GSK-3β, GAP-43, and EGFR [47]. Thus, another cPKC isoform
(s) could also be involved in S373 phosphorylation of mSK1a, either alone or together with
PKCα, although this was not demonstrated in the present study. Still, the expression and distri-
bution of cPKC isoforms vary between cell types [48]. PKCα are found widely expressed in vari-
ous cell types whereas others seem to be more restricted in their distributions. Presumably, the
relative dominance of PKCα over other cPKC isoforms for the phosphorylation of mSK1a
might be influenced by the expression level of each isoform in the given cell type.
The data presented here provide the first direct mechanistic link between cPKC-dependent
phosphorylation and mSK1a regulation. Our study revealed that mSK1a is negatively regulated
by PKCα-dependent phosphorylation at S373 (Fig 6A). In fact, mSK1a phosphorylation is
inversely correlated with mSK1a activity over every time examined, and simple substitution of
S373 with Glu is sufficient for the constitutive, dramatic inhibition of mSK1a regardless of
PMA treatment. However, it still remains unclear how phosphorylation of mSK1a at this resi-
due modulates enzyme activity. In general, protein modifications such as phosphorylation can
change the activity of the modified enzyme through changes in either protein conformation or
intermolecular interaction with regulatory binding partner(s). Primarily, the interaction of
mSK1a with Ca2+-calmodulin complexes was not affected by phosphorylation or mutation at
S373, suggesting that the altered activity with phosphorylation or mutation of S373 is unlikely
due to interference of the Ca2+-calmodulin-dependent regulation of mSK1a. Also, notwith-
standing the phosphorylation- or S373E substitution-dependent transition to the inactive
form, mSK1a exhibited no visible change in protein–protein interaction(s) (S1 Fig). These
observations imply that the reduced kinase activity in the mutants is not the result of disrupted
protein–protein interactions with a putative regulatory factor. Therefore, we currently favor a
model in which S373 phosphorylation is sufficient to change the intramolecular conformation
of mSK1a into an inactive form. Recent study using X-ray crystallography determined the
structure of the truncated form of residues 9–364 residue of human SK1 (the full-length con-
tains 384 residues) [49]. To date, however, the structure and function of the proline-rich C-ter-
minus of SK1 is yet to be determined. The results of our current study highlight the potential
regulatory importance of the C-terminus of mSK1. In the future, comparison of the protein
structures of full-length mSK1a and the S373E mutant may shed light on the molecular mecha-
nisms of regulation, including structural changes resulting from protein phosphorylation at the
C-terminus of mSK1a. On the other hand, SK1 protein is exported into the extracellular
medium [50, 51], which led us to carefully examine if PMA-induced inhibition of mSK1a is
attributable to any unnoticed alteration in the protein level of mSK1a in the tested cells. As
shown in multiple figures, neither PMA treatment nor S373 mutation altered the protein level
of mSK1a in cells, in contrast to the consistent changes in mSK1a activity. In addition, S1P can
be secreted into culture media upon its synthesis. Furthermore, it is noteworthy that the in
vitromSK1a activity is consistent with the results from the in vivo assay (Fig 2). Collectively,
these results support our conclusion that mSK1a is inhibited by S373 phosphorylation, not by
the extracellular release of mSK1a protein or of its product S1P. Nonetheless, we cannot
exclude the possibility that mSK1a is exported but remains bound to the extracellular surface
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of the plasma membrane without altering the total mSK1a level in cells. In this regard, it would
be interesting to examine if mSK1a S373 phosphorylation can influence the export of mSK1a
protein and its extracellular activity on the surface of the plasma membrane in future studies.
We found that mSK1a is phosphorylated in two distinct sites, S225 and S373. Our results
identify S373 of mSK1a as the cPKC-dependent phosphorylation site, as well as S225 as the
PKC-independent phosphorylation site. A previous report showed that S225 phosphorylation
of hSK1a in response to PMA treatment is mediated by ERK1/2, which plays a key role in
PMA-induced activation of mSK1a by facilitating both membrane translocation and enzymatic
activation of hSK1a [37]. Our result confirmed that phosphorylation at the S225 residue of SK1
is conserved between species. However, it was noteworthy that S225 phosphorylation of
mSK1a is barely sensitive to PMA treatment. In fact, sequence alignment between human and
Fig 6. Schematic representation of cPKC-dependent mSK1a regulation. (A) Phosphorylation-dependent
regulation of mSK1a. (B) Schematic model for mSK1a regulation in response to extracellular stimuli.
Abbreviations: mSK1a (mouse sphingosine kinase 1a), PIP2 (phosphatidylinositol 4,5-bisphosphate), DAG
(diacylglycerol), cPKC (conventional protein kinase C), PMA (phorbol 12-myristate 13-acetate), ERK
(extracellular signal-regulated kinase), CaM (calmodulin), IP3, (inositol trisphosphate), PLC-γ (phospholipase
C-gamma), P (phosphate group).
doi:10.1371/journal.pone.0143695.g006
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mouse mSK1a revealed a meaningful difference in the proline residue immediately adjacent to
the phosphorylated S225 residue (Fig 6A). This proline residue is an essential component of
the consensus motif for ERK1/2 phosphorylation [46]. Presumably, the absence of P226 resi-
due in mSK1a makes the S225 residue of mSK1a less optimal for the phosphorylation by ERK,
which may account for no significant change in S225 phosphorylation by ERK in the cells. In
this regard, S225 phosphorylation of mSK1a is unlikely mediated by ERK1/2, but rather by
another kinase that is insensitive to PMA treatment, suggesting the significant difference in the
signaling pathway to SK1a activation. On the other hand, our current study clearly demon-
strated that mSK1a is inhibited through S373 phosphorylation in response to PMA stimulus,
which is not consistent with the previous report using hSK1a[37]. Of note, we found that S373
of mSK1a is conserved in mouse and rat, but not in human (Fig 6A), indicating that this phos-
phorylation and inhibition of mSK1a happens in species-specific manner. Collectively, distinct
phosphorylation pattern at two mSK1a phosphorylation sites, S225 and S373 may account for
the apparent discrepancy between species regarding PMA-induced SK1a regulation [37]. In
particular, our current observation may contribute to better understanding the molecular basis
underlying the interspecies differences in sphingolipid metabolism in vivo.
In summary, our results demonstrate that mSK1a is inhibited by cPKC-dependent phos-
phorylation, and that mSK1a phosphorylation is mediated specifically and directly by cPKC.
We also demonstrated that phosphorylation at S373, located in the C-terminal regulatory
region, plays a pivotal role in the negative regulation of mSK1a. Nonetheless, we have to admit
that our study was conduced mostly with cell stimulation with PMA, a type of phorbol esters
which does not exist endogenously in mammals, but mimic the action of diacyl glycerol
(DAG), potent activator of PKC [52]. In this regards, the physiological relevance of our obser-
vation may need to be further validated in the research models of mSK1a-dependent cellular
processes including cell proliferation, cell survival, apoptosis, and angiogenesis [2, 45].
In the context of cellular signaling, mSK1a is activated through S225 phosphorylation by
unknown kinase probably downstream of growth factor receptor stimulation (Fig 6B). In paral-
lel, phospholipase C (PLC)-dependent cleavage of PIP2 generates IP3 and diacyl glycerol
(DAG), leading to elevation of intracellular Ca2+ and cPKC activation. The increase in cellular
Ca2+ may result in Ca2+-calmodulin-dependent activation of mSK1a via direct interaction,
whereas cPKC activation may lead to S373 phosphorylation, which results in subsequent inac-
tivation of mSK1a (Fig 6B). This schematic model illustrates the highly dynamic temporal reg-
ulation of mSK1a through distinct phosphorylation events triggered by extracellular stimuli.
Supporting Information
S1 Fig. Effect of mSK1a phosphorylation on its molecular interaction. COS-7 cells were
transfected with control vector, FLAG-tagged mSK1a wild-type (WT), or its S373E mutant
(S373E). After serum deprivation, the cells were treated for 10 min with PMA (100 nM). The cell
lysates were incubated with α-FLAGAffi-Gel. The protein complexes co-immunoprecipitated
with mSK1a were analyzed with SDS-PAGE followed by Coomassie Brilliant Blue (CBB) stain-
ing. Abbreviations: IgGh; Immunoblobulin G heavy chain, IgGl; immunoglobulin G light chain.
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